FDAMA PMA supplement guidance
This article was originally published in The Gray Sheet
FDA releases a draft guidance March 26 implementing Sec. 403(b) of the FDA Modernization Act, which calls for the agency to describe: when published matter may be the basis of a supplemental application; data requirements that avoid duplication of previously submitted material; and which supplements are eligible for priority review. The document, available at www.fda.gov/cdrh/modact/modguid.html, is being issued for comment in advance of the FDAMA-mandated May 20 publication date for the final version
You may also be interested in...
Celltrion has announced plans to add a third biopharmaceutical facility and a new global biotechnology research center at the Korean firm’s existing site in Songdo, Incheon, as the firm also revealed record third-quarter financial results.
An upturn in M&A activity across the whole healthcare sector is expected in 2021, with the COVID-19 pandemic and the associated development of a vaccine shining a light on the sector, says a recent survey by Jefferies.
Australian patients with phototoxicity due to the rare condition EPP will now have their first treatment option – provided the drug's developer, Clinuvel, secures reimbursement under the Pharmaceutical Benefits Scheme.